Silverback Therapeutics
Yahoo Finance • 14 hours ago
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary plat... Full story
Yahoo Finance • last year
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024 Resubmission of New Drug Application (NDA) for neffy® anticipated in H1 202... Full story
Yahoo Finance • last year
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy’s potential to be a safe and effective option across patient sub-populatio... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws
NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and d... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc.(SPRY)
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws. On Sep... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws. On Sep... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc.(SPRY) for Potential Violations of Securities Laws
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and d... Full story
Yahoo Finance • last year
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that cou... Full story
Yahoo Finance • last year
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
neffyresulted in robust responses on pharmacodynamic (PD) surrogates of efficacy observed even at 1 minute after dosing, and which were comparable to, or greater in magnitude than, EpiPen Repeat doses of neffy resulted in statistically gre... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. (“ARS”) (NASDAQ: SPRY) concerning possible violations of federal securities laws. On Se... Full story
Yahoo Finance • last year
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under allergen-induced allergic rhinitis conditions FDA Advisory Committee (PADAC), held in May 2... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that c... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Robert S. Willoughby a... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis New Drug and Marketing Authorization Applications for neffyUnder Review with FDA... Full story
Yahoo Finance • 2 years ago
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
FDA Advisory Committee Votes: neffy Data Support a Favorable Benefit-Risk Assessment in Adults (16:6 in Favor) and in Children <18 years of age and ≥30 kg (17:5 in Favor) If Approved, neffy Will Become the First Needle-Free Epinephrine Pro... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for potential securities law violations. Investors who have lost money in their ARS Pharmaceuticals investment should cont... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that co... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial Position with $274.4 Million in Cash, Cash Equivale... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting Data Support New Drug Application for neffy®, Currently Under Review with the FDA SAN DIEGO, Feb. 23, 2023... Full story
Yahoo Finance • 2 years ago
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that c... Full story
